All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lupus Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-04-23T15:43:49.000Z

Lupus Low Disease Activity State in patients with recent onset vs established SLE

Apr 23, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new development in systemic lupus erythematosus.

Lupus low disease activity state (LLDAS) is a validated treat-to-target goal in systemic lupus erythematosus (SLE). However, data on protective associations of LLDAS in newly diagnosed patients to those with established disease is scarce.

Golder et al. recently published an article in The Journal of Rheumatology, comparing attainment and protective effects of LLDAS between inception and non-inception cohort patients from a large multinational prospective longitudinal study. Here, we provide a summary of their findings and an expert opinion by one of the authors, Mandana Nikpour.

Methods1

  • Patients with SLE from a 13-country longitudinal SLE cohort between 2013 and 2020 were studied prospectively.
  • Patients with disease duration <1 year at enrolment were categorized as inception (newly diagnosed) cohort.
  • Primary outcomes assessed were organ damage accrual and occurrence of flare episodes.
  • Patient characteristics between inception and non-inception cohorts were compared.
  • Cox regression analyses were performed to examine the association of:
    • first LLDAS attainment in patients who were not in LLDAS at enrolment; and
    • LLDAS attainment with damage accrual and flare at a subsequent visit.

Key findings1

Patient characteristics

  • A total of 4,100 patients were studied.
    • Median age was 29 years at SLE diagnosis and 92% were female.
    • Median study duration was 2.5 years.
  • The inception cohort (16% of patients) was younger, and had higher disease activity and medication usage including high-dose glucocorticoids, but had less organ damage at enrolment compared with the non-inception cohort.
    • Fewer inception cohort patients were in LLDAS at enrolment than the non-inception cohort (29.6% vs 52.3%; p<0.001), yet three-quarters of both cohorts attained LLDAS at least once during follow-up.

Time to first LLDAS attainment

  • Among patients not in LLDAS at enrolment, inception cohort patients attained LLDAS significantly faster and were about 60% more likely to achieve LLDAS than non-inception cohort patients (hazard ratio = 1.60; p < 0.0001).

LLDAS attainment and organ damage accrual

  • Unlike the inception cohort, a statistically significant negative association between LLDAS attainment and organ damage accrual was observed in the non-inception cohort.

LLDAS attainment and flare

  • Attaining LLDAS significantly reduced the risk of flare at subsequent visits in both the inception and non-inception cohorts.
  • Compared with patients not attaining LLDAS, inception cohort patients attaining LLDAS by 6 months were significantly less likely to have flares by 12 and 24 months after enrolment (Figure 1).

Figure 1. Impact of LLDAS attainment within 6 months on damage accrual and flare in newly diagnosed patients with SLE* 

DA, damage accrual; LLDAS, Lupus Low Disease Activity State. 
*Data from Golder, et al.1 Created with BioRender.com.
p = 0.0011.
p = 0.0023.

 

Key learnings
  • Consistent with the natural history of SLE, newly diagnosed patients had higher disease activity, more flares, and received more treatment. Nevertheless, these patients attained LLDAS faster than those with established SLE and experienced fewer flares when attaining LLDAS within 6 months.
  • LLDAS attainment was also protective against damage accrual and flare in patients with established disease.
  • These findings endorse attaining LLDAS as a clinical treatment target in both newly diagnosed and established SLE.


Question for expert


Expert Opinion

This study confirms that LLDAS is a feasible state that under usual care conditions is achieved in a significant proportion, albeit not all patients. The observation that inception cohort patients attain LLDAS significantly faster and with a 60% greater likelihood than non-inception cohort patients points to the attainability of LLDAS in the context of recent onset disease where clinicians are often treating aggressively to control disease activity, allowing tapering of corticosteroids to the daily threshold of 7.5 mg or less. While LLDAS attainment was associated with reduced risk of flares in both inception and non-inception cohorts, it was only associated with statistically reduced likelihood of damage accrual in the non-inception cohort, possibly due to the relatively short period of follow-up in the study. Longer follow-up of the incident cohort is needed to confirm the protective association of LLDAS against damage accrual in this subgroup.

  1. Golder V, Kandane-Rathnayake R, Louthrenoo W, et al. Comparison of attainment and protective effects of lupus low disease activity state in patients with newly diagnosed versus established SLE. J Rheumatol. 2024. Online ahead of print. DOI: 3899/jrheum.2023-0900.

Newsletter

Subscribe to get the best content related to lupus delivered to your inbox